https://doi.org/10.55788/bc17d581
MESA was set up to study the correlates, predictors, and progression of subclinical CVD in a diverse population of 6,814 Americans between the ages of 45 and 84 years who had no evidence of clinical CVD at baseline. As the specific vascular contributions to dementia remain insufficiently understood, MESA set up a study to identify the correlates of incident dementia in a cardiovascular cohort. The results were presented as a poster at the ACC 2023 meeting by Dr Mohammad Ostovaneh (Johns Hopkins Hospital, MD, USA) [1].
The study included 6,806 MESA participants who had sufficient follow-up data for incident dementia. At the baseline exam, MESA collected data on almost 200 variables including demographic risk factors, past medical history, anthropometric measurements, laboratory markers, electrocardiogram, cardiac and aortic MRI, coronary artery calcium, and liver fat. From this data, correlates of incident dementia were identified using Random Survival Forest analysis, a non-parametric machine learning strategy to build a risk prediction model of survival.
Dr Ostovaneh and colleagues identified 326 cases of dementia over the course of 14 years. Beyond age, the major independent correlates of dementia included:
- coronary artery calcification;
- high-sensitivity troponin;
- common carotid artery intima-media thickness;
- N-terminal prohormone of brain natriuretic peptide (NT-proBNP);
- physical activity;
- pulse pressure;
- tumour necrosis factor-α;
- a history of cancer; and
- liver-to-spleen attenuation ratio.
The researchers added that participants over 62 years at baseline had similar dementia correlates to the cohort as a whole but, in this subgroup, IL-2 soluble receptor, apolipoprotein E, and descending aortic strain were also associated with dementia.
- Ostovaneh M, et al. Deep phenotyping of dementia in a multi-ethnic cardiovascular cohort: The multi-ethnic study of atherosclerosis (MESA). Session 906-09, ACC Scientific Session 2023, 4–6 March, New Orleans, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« HFA 2023 Highlights Podcast Next Article
Half-dose tenecteplase safe and effective for STEMI without timely PCI »
« HFA 2023 Highlights Podcast Next Article
Half-dose tenecteplase safe and effective for STEMI without timely PCI »
Table of Contents: ACC 2023
Featured articles
Pulmonary Arterial Hypertension
Sotatercept improves exercise capacity in patients with PAH
Fixed-dose macitentan plus tadalafil superior to either agent alone in PAH
Coronary Revascularisation
Immediate complete revascularisation non-inferior to staged complete revascularisation
RENOVATE-COMPLEX-PCI results support intravascular-guided PCI for complex lesions
Heart Failure and Cardiomyopathy
No need to restrict vigorous exercise in selected HCM patients?
No difference in CV outcomes between PET or CMR and SPECT
Interventional and Structural Cardiology
Benefits of MitraClip sustained to 5 years in COAPT trial
Transcatheter repair for patients with tricuspid regurgitation
Minimally invasive versus conventional sternotomy for mitral valve repair
Durable benefits of TAVR versus surgical aortic valve replacement in aortic stenosis patients
PCI not better than GDMT in severe ischaemic cardiomyopathy
Prevention
Anticoagulation in non-critically ill hospitalised COVID patients
Statins associated with reduced heart dysfunction from anthracyclines
Multifaceted strategy improves prescription of therapies for diabetes and ASCVD
Dyslipidaemia
Bempedoic acid benefits statin-intolerant patients at high cardiovascular risk
Evolocumab improves coronary plaque morphology in stable CAD
Inflammation stronger predictor of MACE than cholesterol levels
Oral PCSK9 inhibitor significantly lowers LDL-C
Miscellaneous
Baxdrostat in patients with uncontrolled hypertension
Hormone therapy for gender dysphoria associated with increased CV risk
Pulsed-field ablation appears safe and effective for atrial fibrillation
Key correlates of incident dementia identified in the MESA study
Related Articles
July 30, 2019
Two experimental antibodies reduce amyloid levels
August 27, 2019
A necessary shift of focus to the earlier stages of Alzheimer’s
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy